Lifeboat Foundation

Writing a report on the state of AI must feel a lot like building on shifting sands: By the time you hit publish, the whole industry has changed under your feet. But there are still important trends and takeaways in Stanford’s 386-page bid to summarize this complex and fast-moving domain.

The AI Index, from the Institute for Human-Centered Artificial Intelligence, worked with experts from academia and private industry to collect information and predictions on the matter. As a yearly effort (and by the size of it, you can bet they’re already hard at work laying out the next one), this may not be the freshest take on AI, but these periodic broad surveys are important to keep one’s finger on the pulse of industry.

This year’s report includes “new analysis on foundation models, including their geopolitics and training costs, the environmental impact of AI systems, K-12 AI education, and public opinion trends in AI,” plus a look at policy in a hundred new countries.

There are approximately 30 trillion cells in a human body and our health is predicated on them properly interacting with and supporting each other, with the immune system playing a particularly pivotal role. One of the defining characteristics of aging is a decline in the proper functioning of our immune system. Centenarians, a rare population of individuals who reach 100 years or more, experience delays in aging-related diseases and mortality which suggests their immune systems remain functional into extreme old age.

Led by researchers from Boston University Chobanian & Avedisian School of Medicine and Tufts Medical Center, a new study finds centenarians harbor distinct immune cell type composition and activity and possess highly functional immune systems that have successfully adapted to a history of sickness allowing for exceptional longevity. These immune cells may help identify important mechanisms to recover from disease and promote longevity.

“Our data support the hypothesis that centenarians have protective factors that enable to recover from disease and reach extreme old ages,” said lead author Tanya Karagiannis, Ph.D., senior bioinformatician, Center for Quantitative Methods and Data Science, Institute for Clinical Research and Health Policy Studies at Tufts Medical Center.

Anti AI / AI ethics clowns now pushing.gov for some criminalization, on cue.

A nonprofit AI research group wants the Federal Trade Commission to investigate OpenAI, Inc. and halt releases of GPT-4.

OpenAI “has released a product GPT-4 for the consumer market that is biased, deceptive, and a risk to privacy and public safety. The outputs cannot be proven or replicated. No independent assessment was undertaken prior to deployment,” said a complaint to the FTC submitted today by the Center for Artificial Intelligence and Digital Policy (CAIDP).

Continue reading “GPT-4 poses too many risks and releases should be halted, AI group tells FTC” »

Reliable carbon-free power for the world — michelle catts, senior vice president, nuclear programs, ge-hitachi nuclear energy.

Michelle Catts is the Senior Vice President of Nuclear Programs at GE-Hitachi (GEH — https://nuclear.gepower.com/) located in Wilmington, NC.

Continue reading “Michelle Catts — SVP, Nuclear Programs, GE-Hitachi — Reliable Carbon-Free Power For The World” »

Regeneration, Resuscitation & Biothreat Countermeasures — Commander Dr. Jean-Paul Chretien, MD, Ph.D., Program Manager, Biological Technology Office, DARPA

Commander Dr. Jean-Paul Chretien, MD, Ph.D. (https://www.darpa.mil/staff/cdr-jean-paul-chretien) is a Program Manager in the Biological Technology Office at DARPA, where his research interests include disease and injury prevention, operational medicine, and biothreat countermeasures. He is also responsible for running the DARPA Triage Challenge (https://triagechallenge.darpa.mil/).

Continue reading “CDR Dr. Jean-Paul Chretien — DARPA BTO — Regeneration, Resuscitation And Biothreat Countermeasures” »

Dedicated to ending the HIV epidemic — dr. moupali das, MD, MPH, executive director, HIV clinical research, gilead sciences.

Dr. Moupali Das, MD, MPH, is Executive Director, HIV Clinical Research, in the Virology Therapeutic Area, at Gilead Sciences (https://www.gilead.com/), where she leads the pre-exposure prophylaxis (PrEP) clinical drug development program, including evaluating the safety and efficacy of a long-acting, twice yearly, subcutaneous injection being studied for HIV prevention. Her responsibilities also include expanding the populations who may benefit from PrEP.

Continue reading “Dr. Moupali Das, MD, MPH — Gilead Sciences — Dedicated To Ending The HIV Epidemic” »

Blake Lemoine, the Google engineer fired for violating the company’s confidentiality policy, has now expressed concerns about the risks associated with AI-driven chatbots like Microsoft’s Bing AI.

The latest AI models, according to him, are the most potent technological advancement since the atomic bomb and can alter the course of history fundamentally.

As the ChatGPT and Whisper APIs launch this morning, OpenAI is changing the terms of its API developer policy, aiming to address developer — and user — criticism.

Starting today, OpenAI says that it won’t use any data submitted through its API for “service improvements,” including AI model training, unless a customer or organization opts in. In addition, the company is implementing a 30-day data retention policy for API users with options for stricter retention “depending on user needs,” and simplifying its terms and data ownership to make it clear that users own the input and output of the models.

Greg Brockman, the president and chairman of OpenAI, asserts that some of these changes aren’t changes necessarily — it’s always been the case that OpenAI API users own input and output data, whether text, images or otherwise. But the emerging legal challenges around generative AI and customer feedback prompted a rewriting of the terms of service, he says.

Advancing Biomedical R&D & Clinical Development In Saudi Arabia — Dr. Abdelali Haoudi, Ph.D., Managing Director, Biotechnology Park, King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs.

Dr. Abdelali Haoudi, Ph.D. (https://kaimrc-biotech.org.sa/dr-abdelali-haoudi/) currently leads Strategy and Business Development functions, and is also Managing Director of the Biotechnology Park, at King Abdullah International Medical Research Center, at the Ministry of National Guard Health Affairs. He is also Distinguished Scholar at Harvard University-Boston Children’s Hospital.

Continue reading “Dr. Abdelali Haoudi, PhD — KAIMRC — Advancing Biomedical R&D & Clinical Development In Saudi Arabia” »